BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 9869569)

  • 1. Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis.
    Entenza JM; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 1999 Jan; 43(1):77-84. PubMed ID: 9869569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci.
    Entenza JM; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 2004 Jan; 48(1):86-92. PubMed ID: 14693523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
    Entenza JM; Que YA; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3076-83. PubMed ID: 11600359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group streptococcus or Staphylococcus aureus.
    Chambers HF; Xiang Q; Liu ; Chow LL; Hackbarth C
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2742-6. PubMed ID: 10543757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus.
    Entenza JM; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 1997 Aug; 41(8):1662-7. PubMed ID: 9257737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy of trovafloxacin in experimental endocarditis caused by ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus.
    Kim YS; Liu Q; Chow LL; Chambers HF; Täuber MG
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3325-7. PubMed ID: 9835540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trovafloxacin treatment of viridans group Streptococcus experimental endocarditis.
    Piper KE; Rouse MS; Ronningen KL; Steckelberg JM; Wilson WR; Patel R
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2554-6. PubMed ID: 10952616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci.
    Entenza JM; Caldelari I; Glauser MP; Moreillon P
    J Antimicrob Chemother; 1999 Dec; 44(6):775-86. PubMed ID: 10590278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections.
    Endtz HP; Mouton JW; den Hollander JG; van den Braak N; Verbrugh HA
    Antimicrob Agents Chemother; 1997 May; 41(5):1146-9. PubMed ID: 9145886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis.
    Entenza JM; Marchetti O; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 1998 Aug; 42(8):1889-94. PubMed ID: 9687379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis.
    Kaatz GW; Seo SM; Aeschlimann JR; Houlihan HH; Mercier RC; Rybak MJ
    Antimicrob Agents Chemother; 1998 Feb; 42(2):254-6. PubMed ID: 9527768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to trovafloxacin.
    Bonilla HF; Zarins LT; Bradley SF; Kauffman CA
    Diagn Microbiol Infect Dis; 1996 Sep; 26(1):17-21. PubMed ID: 8950524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis.
    Kaatz GW; Seo SM; Lamp KC; Bailey EM; Rybak MJ
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1192-7. PubMed ID: 1329613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response of complicated methicillin-resistant Staphylococcus aureus endocarditis to the addition of trovafloxacin.
    Eckart RE; Hospenthal DR; Fishbain JT
    Pharmacotherapy; 2000 May; 20(5):589-92. PubMed ID: 10809347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model.
    Firsov AA; Vasilov RG; Vostrov SN; Kononenko OV; Lubenko IY; Zinner SH
    J Antimicrob Chemother; 1999 Apr; 43(4):483-90. PubMed ID: 10350376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enoxacin compared with vancomycin for the treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis.
    Gilbert M; Boscia JA; Kobasa WD; Kaye D
    Antimicrob Agents Chemother; 1986 Mar; 29(3):461-3. PubMed ID: 3459391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
    Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
    Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LB11058, a new cephalosporin with high penicillin-binding protein 2a affinity and activity in experimental endocarditis due to homogeneously methicillin-resistant Staphylococcus aureus.
    Vouillamoz J; Entenza JM; Hohl P; Moreillon P
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4322-7. PubMed ID: 15504859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effect of trovafloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in a murine sepsis model.
    Lacy MK; Nicolau DP; Banevicius MA; Nightingale CH; Quintiliani R
    J Antimicrob Chemother; 1999 Oct; 44(4):477-81. PubMed ID: 10588309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.